Valuation: ADC Therapeutics SA

Market Cap 157M 137M 129M 118M 221M 15.01B 221M 1.55B 597M 7.67B 590M 577M 24.71B P/E 2026 *
-1.62x
P/E 2027 * -1.82x
Enterprise Value 157M 137M 129M 118M 221M 15.01B 221M 1.55B 597M 7.67B 590M 577M 24.71B EV / Sales 2026 *
1.95x
EV / Sales 2027 * 1.54x
Free-Float
83.9%
Yield 2026 *
-
Yield 2027 * -
1 day+2.85%
1 week+18.57%
Current month+6.41%
1 month+29.00%
3 months+8.26%
6 months-69.26%
Current year-64.73%
1 week 1.01
Extreme 1.01
1.29
1 month 0.95
Extreme 0.9514
1.37
Current year 0.78
Extreme 0.7796
4.98
1 year 0.78
Extreme 0.7796
4.98
3 years 0.36
Extreme 0.359908
6.04
5 years 0.36
Extreme 0.359908
32
10 years 0.36
Extreme 0.359908
56.59
Manager TitleAgeSince
Chief Executive Officer 53 09/05/2022
Director of Finance/CFO 54 19/12/2022
Chief Tech/Sci/R&D Officer 52 01/10/2024
Director TitleAgeSince
Director/Board Member 67 01/06/2019
Director/Board Member 53 01/06/2018
Chairman 59 01/03/2020
Date Insider Type Main position Quantity % Market Cap. Importance
30/06/26 Free

Chief Executive Officer

675,000 0.5307%
30/06/26 Free

Chief Financial Officer

203,700 0.1602%
30/06/26 Free

Chief Technology Officer

213,900 0.1682%
Change 5-day change 1-year change 3-year change Capi.($)
+3.25%+18.57%-63.17%+53.99% 157M
+0.06%+7.20%+54.04%+111.13% 74.27B
-2.29%-1.51%+33.30%+75.15% 61.21B
+0.28%+7.27%+31.74%+23.80% 27.55B
-1.86%-2.82%-18.06%+362.06% 26.38B
-1.39%+4.69%+2.09%-2.72% 25.34B
+0.57%+3.66%+25.59%-9.08% 20.84B
-1.47%+4.46%-8.09%+513.33% 14.94B
+1.29%-2.49%+163.31%+333.06% 15.17B
-2.60%+0.04%+42.69%+160.22% 14.41B
Average -0.45%+4.17%+26.34%+162.09% 28.03B
Weighted average by Cap. -0.85%+3.09%+35.67%+135.02%

Financials

2026 *2027 *
Net sales 80.65M 70.48M 66.24M 60.45M 113M 7.71B 113M 795M 307M 3.94B 303M 296M 12.69B 102M 89.11M 83.75M 76.43M 143M 9.75B 143M 1.01B 388M 4.98B 383M 375M 16.05B
Net income -120M -105M -98.45M -89.84M -169M -11.46B -169M -1.18B -456M -5.85B -450M -440M -18.87B -118M -103M -96.72M -88.26M -166M -11.26B -166M -1.16B -448M -5.75B -442M -433M -18.53B
Net Debt - -
Logo ADC Therapeutics SA
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.
Employees
191
Date Price Change Volume
23/09/26 $1.245 +1.22% 909,123
22/09/26 $1.230 +9.82% 1,674,295
21/09/26 $1.120 +6.67% 1,899,275
18/09/26 $1.050 -0.94% 1,580,274
17/09/26 $1.060 +0.95% 1,545,569
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.230USD
Average target price
3.333USD
Spread / Average Target
+171.00%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ADCT Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!